AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06119022 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: routine medical treatment
Description: Patients with negative myocardial ischemia either in CT-MPI guided arm or SPECT-MPI guided arm will scheduled to have routine medical therapy instead of invasive coronary angiography.
Study NCT05573685 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo App
Description: Placebo App to be used in patients with 1 of the 4 indications of rheumatoid arthritis, fibromyalgia Irritable Bowel Syndrome, Diabetic Neuropathy
Study NCT05893082 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: F2 Filter and Delivery System
Description: Placement of F2 device in aorta to cover the great cerebral vessels.
Study NCT06338449 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic training (AT)
Description: An exercise program was developed by a full-time physical education teacher, with all group exercises conducted at the outdoor track and field facility of Xuzhou Medical University. Participants in the aerobic training group, after completing a warm-up, were required to perform moderate-intensity aerobic running for 60 minutes per session, 4-5 times a week. The exercise intensity was set to reach 50%-70% of the maximum heart rate (Maximum heart rate = 220 - age). The exercise sessions were scheduled in the evening after dinner, from 17:30 to 19:00.All participants were continuously intervened for 8 weeks.
Study NCT05492032 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active-tDCS
Description: For active-tDCS condition, participants will receive stimulation on the dorsolateral prefrontal cortex with ramp up and ramp down mode for 10 seconds, eliciting a tingling sensation on the scalp that fades over seconds. Following that, a twenty-minute executive functional training task will be initiated five minutes subsequent to the stimulation mode, and the stimulation will be terminated when the training task ends.
Study NCT06338449 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance training (RT)
Description: Participants in the resistance training group were required to complete moderate-intensity resistance exercises 4-5 times per week. Each session included a warm-up, followed by exercises such as knee lifts with torso twists, knee-to-hand taps under the hips, jumping jacks, burpees, sit-ups, planks, and squats. The routine was structured to perform 5-6 exercises per session, with 6-8 repetitions for each set. There was a 30-second rest interval between sets, and the total exercise time was 60 minutes. The timing for these exercise sessions was the same as for the AT group, conducted in the evening after dinner.All participants were continuously intervened for 8 weeks.
Study NCT06517797 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: S1B-509
Description: S1B-509 has multiple neurotransmitter activities
Study NCT06338449 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Combined aerobic and resistance training (AT + RT)
Description: Participants in the combined aerobic and resistance training (AT+RT) group started their sessions with a warm-up, followed by 30 minutes of aerobic running. After the aerobic training, they engaged in resistance training. The resistance training regimen was the same as that for the RT group, except that the duration of the resistance training was shorter. The total duration of the exercise session was 60 minutes.All participants were continuously intervened for 8 weeks.
Study NCT06388720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin-c 40mg/20ml and Gemcitabine 2000mg/50ml
Description: Intravesical sequential treatment of Mitomycin-c 40mg/20ml and Gemcitabine 2000mg/50ml.
Study NCT06342167 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Interventions consist of 50-60 Gy in 25-30 fractions of radiotherapy.
Study NCT06342167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Programmed Cell Death Protein 1 Inhibitor
Description: 200 mg of Sintilimab administered every three weeks concurrently with radiotherapy and after radiotherapy as consolidation therapy up to 1year.
Study NCT06342167 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immunonutrition support
Description: 600-1600 ml of TPF-T per day according to the nutrition status evaluation
Study NCT05153005 — intervention group
Intervention type: OTHER
Intervention: examination methods
Description: Some advanced methods: mannose protein (Mp1p), (1,3)- β- D-glucan (G antigen) and Cryptococcus capsular antigen (CrAg) serological detection, qPCR, dd- PCR and mass spectrometry identification, QFC.
Study NCT05185232 — intervention group
Intervention type: OTHER
Intervention: Impact of gaps in care/loss to healthcare follow-up
Description: There will not be a discrete intervention as part of this study but study investigators will be examining a set of primary and secondary outcomes in patients who have followed recommended cardiac care vs. those who have not.
Study NCT05994651 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tidal Model improvement model
Description: 1. st interview Pre-assessment Application of measurement tools~2. nd meeting Orientation Concept of recovery, change phase of the individual, Holistic Evaluation, Creation of Personal Safety Plan 3. Interview Process planning Setting goals, Starting One-on-One Sessions~4th meeting Healing is possible, accepting his illness, overcoming change, emphasizing his strengths, instilling hope 5.-6. interview Empowerment Coping with crisis, reducing anxiety, relaxation exercises, individual roles, assertiveness, strengthening self-esteem 7.-8. Interview Maintaining control of life, taking responsibility for behavior, appropriate expression of anger, feeling, thinking and Taking responsibility for recovery, discovering behaviors 9th interview Creating a supportive environment Increasing new interactions, relationships, social skills 10th meeting Evaluation Finalizing the personal security plan, using new knowledge and behaviors in the healing journey, evaluation of the process
Study NCT05492032 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham-tDCS
Description: For sham-tDCS condition, participants will receive initial stimulation with ramp up and ramp down mode for 30 seconds, eliciting a tingling sensation on the scalp then it will be discontinued. Participants will also receive the twenty-minute executive functional training task five minutes subsequent to the stimulation mode.
Study NCT05492032 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: Participants will complete an online cognitive training program consisting of 10 consecutive daily weekday training sessions while they receive either the active or sham tDCS stimulation. Each training session will last for 20 minutes. The online cognitive training program will comprise five exercises assessing information processing speed and executive function capacities. Each exercise will take approximately 4 minutes to complete. Given many studies, across different neurological/neuropsychiatric diagnoses, especially for people with autism, it has long been established that social skills and functioning are closely related, and multiple studies have shown that executive function training can improve social functioning in autism or vice versa (i.e. social skills training improves executive functioning in autism), it is reasonable to include cognitive training in this tDCS protocol.
Study NCT05457452 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Knee Brace
Description: Installation of an angle-adjustable knee brace, used after ACL reconstruction performed by an orthopedic specialist or orthopedic PPDS with the first week the angle locked at 00, in the second week the angle 0-900, in the third week the angle 0-1200, and the fourth week the angle of flexion full. Braces are used except for physical therapy according to the rehabilitation protocol in the first week.
Study NCT06517797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1B-509
Description: S1B-509 has multiple neurotransmitter activities
Study NCT05999539 — intervention group
Intervention type: DEVICE
Intervention: Transtibial prosthesis
Description: A transtibial prosthesis to be used for at least one year.
Study NCT05204875 — intervention group
Intervention type: RADIATION
Intervention: X-ray Velocimetry
Description: X-ray Velocimetry (XV) technology images the motion of the lungs, determines airway volumes and measures regional lung ventilation during spontaneous breathing.
Study NCT06633913 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: spTMS-TBS-spTMS
Description: This study uses fMRI in combination with single-pulse TMS (spTMS) and theta-burst stimulation (TBS) to determine if the two effects coming from each are related to one another, and if there will be changes in brain activity when undergoing spTMS that are induced by TBS. Additionally, by stimulating the dlPFC in both patients and healthy controls with this paradigm, researchers are able to specifically compare the after-TBS single-pulse TMS-evoked brain responses with before-TBS responses to observe if TBS will change neural pathways disrupted in those who display high negative affect (e.g. depression, anxiety).
Study NCT06011876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Intermittent Hypoxia (AIH)
Description: AIH (acute intermittent hypoxia) consists of short episodes of low oxygen (9% O2).
Study NCT04757844 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional Near-Infrared Spectroscopy (fNIRS)
Description: The hemodynamic response in prefrontal cortex will be measured using an Octamon+ system (Artinis). Eight emission and two detector probes will be arranged on the participant's forehead.
Study NCT05239195 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video Laryngoscope
Description: Laryngoscope with a camera and a video screen
Study NCT05239195 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Direct Laryngoscope
Description: Laryngoscope without a camera or a video screen
Study NCT06464549 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: EEG-EOG recording at rest and during an auditory oddball paradigm
Description: Participants will attend an electroencephalogram-electrooculogram (EEG-EOG) recording session. Eye blinking will be examined during a rest condition (duration: 8 min) and during an active auditory oddball task (duration: 8 min), consisting of randomly intermixed tones (non-target: 500 Hz, overall probability: 80%, n=312; target: 1000 Hz, overall probability: 20%, n=78) presented with a 1-s inter-stimulus interval through headphones.
Study NCT06370104 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Cognitive Behavioral Therapy for Suicide Prevention
Description: see arm description
Study NCT06370104 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Living under control
Description: see arm description
Study NCT06339762 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Compassion Training
Description: Self-Compassion Training
Study NCT06011876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute Intermittent Hypercapnic-Hypoxia (AIHH)
Description: AIHH consists of short episodes of low oxygen (9% O2) and elevated carbon dioxide (4% CO2).
Study NCT06011876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham AIH
Description: A single session of sham AIH with episodes of normal room air (21% O2).
Study NCT06720389 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: peri implant bone loss was assessed by CBCT
Description: using CBCT, vertical bone loss (VBL) was measured at baseline (T0), at1 year(T1), at 3 years(T3)
Study NCT06720389 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: posterior ridge resorption was assessed by CBCT
Description: posterior ridge resorption was assessed by CBCT at baseline (T0), at 1 year( T1), at 3 years (T3). By superimposition of pre and post CBCT.
Study NCT06728761 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardised test meal
Description: Ingestion of a 1850 Kcal standardised 'Christmas meal' identical for each session. It will consist of the following elements Assortment of Picard Mini-Puff Pastry Aperitifs: 70g = 210 Kcal 1 glass of white wine = 85 Kcal with the aperitif~1 slice of vacuum-packed foie gras = 50 g = 230 Kcal~1 portion of turkey leg 200 g = 250 Kcal 50 g turkey cream = 130 Kcal~1 portion of steamed potatoes = 200 g = 160 Kcal~1 glass of red wine = 85 Kcal to accompany the main course~1 slice of white bread (30 g) = 55 Kcal to eat with the main course Blind test or control drink (trou normand or placebo = water) / 1 scoop of apple sorbet~1 portion 30 g camembert = 90 Kcal + White bread 1 slice (30 g) = 85 Kcal with the cheese~1 portion crumble 100 g = 250 Kcal The different elements will be weighed for each participant.
Study NCT06728761 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standardised test meal
Description: Ingestion of a 1850 Kcal standardised 'Christmas meal' identical for each session. It will consist of the following elements Assortment of Picard Mini-Puff Pastry Aperitifs: 70g = 210 Kcal 1 glass of white wine = 85 Kcal with the aperitif~1 slice of vacuum-packed foie gras = 50 g = 230 Kcal~1 portion of turkey leg 200 g = 250 Kcal 50 g turkey cream = 130 Kcal~1 portion of steamed potatoes = 200 g = 160 Kcal~1 glass of red wine = 85 Kcal to accompany the main course~1 slice of white bread (30 g) = 55 Kcal to eat with the main course Blind test or control drink (trou normand or placebo = water) / 1 scoop of apple sorbet~1 portion 30 g camembert = 90 Kcal + White bread 1 slice (30 g) = 85 Kcal with the cheese~1 portion crumble 100 g = 250 Kcal The different elements will be weighed for each participant.
Study NCT06728761 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ingestion of test drink
Description: Ingestion of 2,5 cl Calvados 40° at the 70th min of the meal (before cheese and dessert)
Study NCT06728761 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ingestion of Control drink
Description: Ingestion of 2,5 cl water at the 70th min of the meal (before cheese and dessert)
Study NCT06728761 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound measurement of the antral area
Description: Ultrasound measurement of the antral area in the volunteers lying in the 45° semi-recumbent position using an ultrasound machine (Venue Go™, GE Healthcare, Chicago, IL, USA) fitted with an abdominal transducer (probe C1-5, 1.5 to 5 MHz) to obtain a sagittal cross-section of the antrum in a plane including the left lobe of the liver and the aorta. This will be performed during the intake visit, immediately before the test drink ingestion (70th min of the meal) and 15, 45, 60, 90, 120, 150, 180 min after the end of the meal
Study NCT06728761 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound measurement of the antral area
Description: Ultrasound measurement of the antral area in the volunteers lying in the 45° semi-recumbent position using an ultrasound machine (Venue Go™, GE Healthcare, Chicago, IL, USA) fitted with an abdominal transducer (probe C1-5, 1.5 to 5 MHz) to obtain a sagittal cross-section of the antrum in a plane including the left lobe of the liver and the aorta. This will be performed during the intake visit, immediately before the test drink ingestion (70th min of the meal) and 15, 45, 60, 90, 120, 150, 180 min after the end of the meal
Study NCT06728761 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Breathalyser for measurement of the level of exhaled ethanol
Description: Breathalyser performed during the intake visit, and 15, 90, 180 and 300 min (if the exhaled alcohol level measured at 180 minutes was greater than 0.25 mg/l of breath) after the end of the meal.
Study NCT05326880 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ceramic Dental Implant
Description: The ceramic implant will be placed in healed extraction sockets in the premolar-to-premolar area in the mandible and maxilla for single tooth replacement followed by prosthetic loading with definitive prosthesis after 6 months healing time. Type 4 surgery will be performed as defined by the ITI Consensus Statements for Implant Placement in Extraction Sockets: healed sites, typically around 16 weeks after tooth was extracted or after tooth was lost to allow complete healing of the ridge as well as soft- and hard tissue maturation. Both SG and CG receive routine treatment, only the choice of the implant material is defined by the study protocol.
Study NCT05326880 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Titanium Dental Implant
Description: The titanium implant will be placed in healed extraction sockets in the premolar-to-premolar area in the mandible and maxilla for single tooth replacement followed by prosthetic loading with definitive prosthesis after 6 months healing time. Type 4 surgery will be performed as defined by the ITI Consensus Statements for Implant Placement in Extraction Sockets: healed sites, typically around 16 weeks after tooth was extracted or after tooth was lost to allow complete healing of the ridge as well as soft- and hard tissue maturation. Both SG and CG receive routine treatment, only the choice of the implant material is defined by the study protocol.
Study NCT06728761 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Breathalyser for measurement of the level of exhaled ethanol
Description: Breathalyser performed during the intake visit, and 15, 90, 180 and 300 min (if the exhaled alcohol level measured at 180 minutes was greater than 0.25 mg/l of breath) after the end of the meal.
Study NCT06728761 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Discomfort
Description: discomfort will be assessed using seven-choice Likert scales immediately before the test drink ingestion and 90 min and 180 min after the end of the standardized meal.
Study NCT05882630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib,Serplulimab,Etoposide,Carboplatin
Description: In dose escalation, Surufatinib will be administered orally (PO) once daily (QD) ,d1-21,q3w + Serplulimab 4.5 mg/kg ivgtt,d1,q3w+Etoposide 100mg/m2,d1-3,q3w + Carboplatin AUC=5,d1,q3w; 4-6 cycles in total.~At the indication-specific expansion portion of the study, patients will receive surufatinib RP2D,d1-21,q3w+Serplulimab 4.5 mg/kg ivgtt,d1,q3w+Etoposide 100mg/m2,d1-3,q3w + Carboplatin AUC=5,d1,q3w, 4-6 cycles in total. After the end of the first-line treatment, patients with CR, PR, and SD can continue to maintenance treatment with Surufatinib RP2D,d1-21,q3w＋Serplulimab 4.5 mg/kg ivgtt,d1,q3w until the disease progressed.
Study NCT06136988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel for Injection (Albumin-bound)
Description: Docetaxel for Injection (Albumin-bound) 60 or 75 mg/m\^2, Intravenous infusion, Q3W
Study NCT06136988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SG001
Description: Recombinant Anti-PD-1 Fully Human Monoclonal Antibody Injection, 360 mg, Intravenous infusion, Q3W
Study NCT06136988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin for injection
Description: Cisplatin for injection, 25 mg/m\^2, Intravenous infusion, D1-D3, Q3W
Study NCT06136988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin for injection
Description: Cisplatin for injection, 25 mg/m\^2, Intravenous infusion, D1-D3, Q3W
Study NCT06136988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 135 mg/m\^2, Intravenous infusion, Q3W
Study NCT06136988 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Simultaneous Radiotherapy
Description: Radiotherapy (28×1.8Gy)
Study NCT06728761 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Discomfort
Description: discomfort will be assessed using seven-choice Likert scales immediately before the test drink ingestion and 90 min and 180 min after the end of the standardized meal.
Study NCT06136988 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Simultaneous Radiotherapy
Description: Radiotherapy (28×1.8Gy)
Study NCT03673735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab (one dose) before CRT and for 6 months Q4W after CRT
Study NCT03673735 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: radiotherapy
Description: radiotherapy is administered in 33 fractions over 6.5 weeks fro a total of 66 Gy
Study NCT03673735 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: radiotherapy is administered in 33 fractions over 6.5 weeks fro a total of 66 Gy
Study NCT03673735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo (one dose) before CRT and for 6 months Q4W after CRT
Study NCT03673735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin (100mg/m2) is administered at day 1, 22, 43 of radiotherapy
Study NCT03673735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin (100mg/m2) is administered at day 1, 22, 43 of radiotherapy
Study NCT05292144 — intervention group
Intervention type: DEVICE
Intervention: Xperience Pro
Description: Patients in whom treatment with (Xperience Pro) has been attempted
Study NCT06728761 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Appetite
Description: Appetite will be assessed using seven-choice Likert scales immediately before the test drink ingestion and 90 min and 180 min after the end of the standardized meal.
Study NCT06728761 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Appetite
Description: Appetite will be assessed using seven-choice Likert scales immediately before the test drink ingestion and 90 min and 180 min after the end of the standardized meal.
Study NCT06728761 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pregnancy urine test carried out during the intake visit on the day of the protocol
Description: Pregnancy urine test carried out during the intake visit on the day of the protocol for exclusion of pregnant woman.